Multiple Sclerosis New Zealand is disappointed Pharmac is only funding treatment for high risk sufferers

Pharmac has announced its funding the Multiple Sclerosis treatment Ocrevus .

MS New Zealand general manager Amanda Rose says the treatment is being prioritised for people who are likely to contract a further condition - which can be life threatening.

But she says lower risk sufferers need to have earlier access to the drug - so their condition doesn't worsen.